Methylene Blue Has Strong Extracellular Virucidal Activity Against a SARS-CoV-2-Related Pangolin Coronavirus with No Intracellular or In Vivo Efficacy
Open Access
Abstract
Studies have demonstrated that methylene blue exhibits significant antiviral activity against SARS-CoV-2 or related coronaviruses at the cellular level, suggesting its potential as an anti-SARS-CoV-2 drug. Herein, we report that methylene blue does not exhibit noticeable antiviral activity in a lethal model involving SARS-CoV-2-related pangolin coronavirus GX_P2V (short_3UTR) infection in CAG-hACE2 transgenic mice. We employed plaque reduction assays and cell infection experiments to compare the extracellular virucidal activity of the compound and its ability to inhibit viral replication in cells to those of nirmatrelvir. Methylene blue demonstrated strong virucidal activity but did not inhibit viral replication in cells. The control compound nirmatrelvir lacked virucidal activity but exhibited strong abilities to inhibit viral replication. The virucidal activity of methylene blue was further tested in mouse plasma. Incubation in mouse plasma increased the virucidal EC50 value of methylene blue, indicating that mouse plasma can affect the stability of the compound, although mouse plasma has some extent of natural virucidal activity. These findings elucidate why methylene blue lacks antiviral efficacy in vivo and provide insights for the development of antiviral drugs.Keywords
Funding Information
- NSFC-MFST project (China–Mongolia) (32161143027, SKLPBS2250)
- Foundation of State Key Laboratory of Pathogen and Biosecurity (32161143027, SKLPBS2250)
This publication has 20 references indexed in Scilit:
- Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTREmerging Microbes & Infections, 2022
- Evaluation of methylene blue based photodynamic inactivation (PDI) against intracellular B-CoV and SARS-CoV2 viruses under different light sources in vitro as a basis for new local treatment strategies in the early phase of a Covid19 infectionPhotodiagnosis and Photodynamic Therapy, 2021
- Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigationsBiomedicine & Pharmacotherapy, 2021
- Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitroScientific Reports, 2021
- Antiviral photodynamic therapy: Inactivation and inhibition of SARS-CoV-2 in vitro using methylene blue and RadachlorinPhotodiagnosis and Photodynamic Therapy, 2021
- Methylene blue inhibits replication of SARS-CoV-2 in vitroInternational Journal of Antimicrobial Agents, 2020
- Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus modelChinese Medical Journal, 2020
- Inactivation of Zika virus in plasma and derivatives by four different methodsJournal of Medical Virology, 2019
- Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectivelyTransfusion, 2018
- Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible LightVox Sanguinis, 1991